title: Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
abstract: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries.
  
  
  
  We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation chemotherapy only.
  
  
  
  The 5-year overall survival (OS) of the high-dose Ara-c group (HDAC; 2≤ Ara-c ≤3 g/m2), intermediate-dose Ara-c group (MDAC; 1.0≤ Ara-c <2.0 g/m2), low-dose Ara-c group (LDAC; 0.2< Ara-c <1.0 g/m2) and standard-dose Ara-c group (SDAC; 0.1≤ Ara-c ≤0.2 g/m2) were 65.3, 39.4, 25.2 and 27.9%, respectively (p = 0.003). In the HDAC group, but not in the MDAC group, the 5-year OS of patients who achieved 3-4 cycles of chemotherapy was superior to those who underwent 1-2 cycles (84.4 vs. 43.6%, p < 0.05), and the 3-year OS of patients who achieved an accumulated 36 g/m2 of Ara-c was significantly higher compared to those who did not (85.3 vs. 39.2%, p < 0.05). Multivariate analysis indicated that factors such as WBC >3.5 × 109/l, PLT ≤30 × 109/l, and extramedullary infiltration were associated with a poor prognosis.
  
  
  
  The survival of t(8;21) AML patients treated with high-dose Ara-c (≥2 g/m2) was superior to other dose levels in postremission consolidation chemotherapy. Patient survival was improved by 3-4 cycles of chemotherapy with an accumulated concentration of 36 g/m2 of Ara-c. WBC >3.5 × 109/l, PLT ≤30 × 109/l and extramedullary infiltration could be indicative of a poor clinical prognosis.
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Gong
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Liang-Ding
authors.initials: LD
authors.lastname: Hu
authors.forename: Jian-Liang
authors.initials: JL
authors.lastname: Shen
authors.forename: Mei-Yun
authors.initials: MY
authors.lastname: Fang
authors.forename: Qing-Ming
authors.initials: QM
authors.lastname: Yang
authors.forename: Heng-Xiang
authors.initials: HX
authors.lastname: Wang
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
authors.forename: Hui-Ren
authors.initials: HR
authors.lastname: Chen
authors.forename: Zhao
authors.initials: Z
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.forename: Yi-Gai
authors.initials: YG
authors.lastname: Ma
authors.forename: Jing-Wen
authors.initials: JW
authors.lastname: Wang
authors.forename: Hong-Hua
authors.initials: HH
authors.lastname: Li
authors.forename: Quan-Shun
authors.initials: QS
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.forename: Xiao-Ning
authors.initials: XN
authors.lastname: Gao
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Dou
authors.forename: Yong-Hui
authors.initials: YH
authors.lastname: Li
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Luo
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D002681:China; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine